J. Carlos Tutor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
J. Carlos Tutor has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Jesús Hermida
2 shared publicationsAlmudena Garcia
Unidad Monitorización Fármacos, Laboratorio Central, Hospital Clínico Universitario, 15706 Santiago de Compostela, Spain
1 shared publicationF.Javier Vadillo
Servicio de Neurologı́a, Hospital Clı́nico Universitario, Santiago de Compostela, Spain
1 shared publicationJ. Antonio Casal
Central Laboratory, Hospital Clinico Universitario, Santiago de Compostela, Spain
1 shared publicationJ. Carlos Guinarte
Laboratorio Central, Hospital Clínico Universitario, Santiago de Compostela, Spain
1 shared publication- J. Carlos Tutor
Unidad Monitorización Fármacos, Laboratorio Central, Hospital Clínico Universitario, Santiago de Compostela, Spain
1 shared publication
Latest Publications
- Open Access
- 29 December 2010
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 116 (2) , 148-154
A preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid
Patients treated with valproic acid (VPA) present a high incidence of non-alcoholic fatty liver disease (NAFLD) (around 61%). Several recent studies suggest that low copper stores could be associated with NAFLD, and a significant decrease of copper availability in VPA-treated patients has been described. In 101 adult epileptic patients treated with valproic acid in monotherapy (n = 75) and polytherapy (n = 26) the copper availability was evaluated using the specific oxidase activity of ceruloplasmin (activity per unit mass of enzyme protein) and the copper/ceruloplasmin ratio. Copper deficiency was supposed in the cases in which this biochemical variable was smaller than the lower reference limit (333 U/g). The differences between the groups of patients with ceruloplasmin oxidase activity smaller or greater than 333 U/g for the serum levels of aminotransferases, gamma-glutamyltransferase, butyrylcholinesterase, cholesterol, triglycerides, and C-reactive protein, and the APRI and FIB-4 liver fibrosis scores were not statistically significant. Most patients (93%) had low APRI and FIB-4 scores, suggesting absence of significant liver fibrosis. The results obtained do not confirm the hypothesis of an association between diminished copper availability and NAFLD in patients treated with valproic acid.
- 29 December 2010
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 116 (2) , 148-154
Open AccessA preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid
Patients treated with valproic acid (VPA) present a high incidence of non-alcoholic fatty liver disease (NAFLD) (around 61%). Several recent studies suggest that low copper stores could be associated with NAFLD, and a significant decrease of copper availability in VPA-treated patients has been described. In 101 adult epileptic patients treated with valproic acid in monotherapy (n = 75) and polytherapy (n = 26) the copper availability was evaluated using the specific oxidase activity of ceruloplasmin (activity per unit mass of enzyme protein) and the copper/ceruloplasmin ratio. Copper deficiency was supposed in the cases in which this biochemical variable was smaller than the lower reference limit (333 U/g). The differences between the groups of patients with ceruloplasmin oxidase activity smaller or greater than 333 U/g for the serum levels of aminotransferases, gamma-glutamyltransferase, butyrylcholinesterase, cholesterol, triglycerides, and C-reactive protein, and the APRI and FIB-4 liver fibrosis scores were not statistically significant. Most patients (93%) had low APRI and FIB-4 scores, suggesting absence of significant liver fibrosis. The results obtained do not confirm the hypothesis of an association between diminished copper availability and NAFLD in patients treated with valproic acid.
- 7 September 2009
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 34 (5) , 531-537
Two sampling time profiles for the abbreviated estimation of mycophenolic acid area under the curve in adult renal transplant recipients treated with mycophenolate mofetil and concomitant tacrolimus
Objective: Various studies have revealed that mycophenolic acid (MPA) area under the time‐concentration curve (AUC) may have clinical value in mycophenolate mofetil dose adjustment. As the full AUC measurement is impractical in clinical practice, several abbreviated AUC profiles using pre‐dose, and two or three post‐dose samples have been proposed; however, the possible use of lower sampling time profiles has an unquestionable practical interest, and the aim of our study was the evaluation of several two‐points algorithms using only one post‐dose sample. Patients and methods: In 60 MPA concentration‐time profiles from 37 adult renal transplant patients treated with mycophenolate mofetil and concomitant tacrolimus, the MPA AUC values were estimated using the three sampling time algorithm (pre‐dose, one‐half and 2 h post‐dose) of Pawinski et al. (Clinical Chemistry 48, 2002, 1497), trapezoidal extrapolated procedure according to Hale et al. (Clinical Pharmacology Therapeutics 64, 1998, 672), and two‐points algorithm (pre‐dose and 2 h post‐dose) proposed by David‐Neto et al. (Clinical Transplantation 19, 2005,19). Results: The AUC values estimated using the algorithm of Pawinski et al. had a very high correlation (r = 0·997, P < 0·001) with the trapezoidal extrapolated AUC results. The estimated AUC values obtained using the two‐points algorithm of David‐Neto et al. present a high correlation (r = 0·930, P < 0·001), acceptable mean prediction error (+3·3 ± 1·8%), and a diagnostic efficiency of 94% in the classification of subtherapeutic, therapeutic, and supratherapeutic values, with respect to the three‐points algorithm of Pawinski et al. Conclusion: The two sampling time algorithm of David‐Neto gave similar results to those of the three‐sampling time algorithm of Pawinski, and both, with sampling over 2 h, may be useful for routine MPA AUC estimation in renal transplant recipients with concomitant tacrolimus. Both are unsuitable when unusually unpredictable pharmacokinetics are expected such as with enteric‐coated formulations.
- 7 September 2009
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 34 (5) , 531-537
Two sampling time profiles for the abbreviated estimation of mycophenolic acid area under the curve in adult renal transplant recipients treated with mycophenolate mofetil and concomitant tacrolimus
Objective: Various studies have revealed that mycophenolic acid (MPA) area under the time‐concentration curve (AUC) may have clinical value in mycophenolate mofetil dose adjustment. As the full AUC measurement is impractical in clinical practice, several abbreviated AUC profiles using pre‐dose, and two or three post‐dose samples have been proposed; however, the possible use of lower sampling time profiles has an unquestionable practical interest, and the aim of our study was the evaluation of several two‐points algorithms using only one post‐dose sample. Patients and methods: In 60 MPA concentration‐time profiles from 37 adult renal transplant patients treated with mycophenolate mofetil and concomitant tacrolimus, the MPA AUC values were estimated using the three sampling time algorithm (pre‐dose, one‐half and 2 h post‐dose) of Pawinski et al. (Clinical Chemistry 48, 2002, 1497), trapezoidal extrapolated procedure according to Hale et al. (Clinical Pharmacology Therapeutics 64, 1998, 672), and two‐points algorithm (pre‐dose and 2 h post‐dose) proposed by David‐Neto et al. (Clinical Transplantation 19, 2005,19). Results: The AUC values estimated using the algorithm of Pawinski et al. had a very high correlation (r = 0·997, P < 0·001) with the trapezoidal extrapolated AUC results. The estimated AUC values obtained using the two‐points algorithm of David‐Neto et al. present a high correlation (r = 0·930, P < 0·001), acceptable mean prediction error (+3·3 ± 1·8%), and a diagnostic efficiency of 94% in the classification of subtherapeutic, therapeutic, and supratherapeutic values, with respect to the three‐points algorithm of Pawinski et al. Conclusion: The two sampling time algorithm of David‐Neto gave similar results to those of the three‐sampling time algorithm of Pawinski, and both, with sampling over 2 h, may be useful for routine MPA AUC estimation in renal transplant recipients with concomitant tacrolimus. Both are unsuitable when unusually unpredictable pharmacokinetics are expected such as with enteric‐coated formulations.
- 1 November 2007
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 47 (11) , 1450-1455
Estimation of the Glomerular Filtration Rate From Serum Creatinine and Cystatin C With Regard to Therapeutic Digoxin Monitoring1
- 1 November 2007
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 47 (11) , 1450-1455
Estimation of the Glomerular Filtration Rate From Serum Creatinine and Cystatin C With Regard to Therapeutic Digoxin Monitoring1
- 1 September 2005
- Published by Elsevier in Kidney International
- Vol. 68 (3) , 948-954
A comparative study of three kidney biomarker tests in autosomal-dominant polycystic kidney disease
- 1 September 2005
- Published by Elsevier in Kidney International
- Vol. 68 (3) , 948-954
A comparative study of three kidney biomarker tests in autosomal-dominant polycystic kidney disease
- Open Access
- 1 June 2004
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 37 (6) , 777-783
Biochemical characterization of the GM2 gangliosidosis B1 variant
The deficiency of the A isoenzyme of ß-hexosaminidase (Hex) produced by different mutations of the gene that codes for the alpha subunit (Tay-Sachs disease) has two variants with enzymological differences: the B variant consists of the absence of Hex A isoenzyme and the B1 variant produces an inactive Hex A isoenzyme for the hydrolysis of the GM2 ganglioside and synthetic substrates with negative charge. In contrast to the early childhood form of the B variant, the B1 variant appears at a later clinical stage (3 to 7 years of age) with neurodegenerative symptoms leading to the death of the patient in the second decade of life. The most frequent mutation responsible for the GM2 gangliosidosis B1 variant is R178H, which has a widespread geographic and ethnic distribution. The highest incidence has been described in Portugal, which has been suggested as the point of origin of this mutation. Biochemical characterization of this lysosomal disease is carried out using negatively charged synthetic alpha subunit-specific sulfated substrates, since Hex A isoenzyme heat-inactivation assays are not applicable. However, the determination of the apparent activation energy of Hex using the neutral substrate 3,3'-dichlorophenolsulfonphthaleinyl N-acetyl-ß-D-glucosaminide, may offer a valid alternative. The presence of an alpha subunit in the alphaß heterodimer Hex A means that its activation energy (41.8 kJ/mol) is significantly lower than that of the ßß homodimer Hex B (75.1 kJ/mol); however, as mutation inactivates the alpha subunit, the Hex A of the B1 variant presents an activation energy that is similar to that of the Hex B isoenzyme.
- 1 June 2004
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 37 (6) , 777-783
Open AccessBiochemical characterization of the GM2 gangliosidosis B1 variant
The deficiency of the A isoenzyme of ß-hexosaminidase (Hex) produced by different mutations of the gene that codes for the alpha subunit (Tay-Sachs disease) has two variants with enzymological differences: the B variant consists of the absence of Hex A isoenzyme and the B1 variant produces an inactive Hex A isoenzyme for the hydrolysis of the GM2 ganglioside and synthetic substrates with negative charge. In contrast to the early childhood form of the B variant, the B1 variant appears at a later clinical stage (3 to 7 years of age) with neurodegenerative symptoms leading to the death of the patient in the second decade of life. The most frequent mutation responsible for the GM2 gangliosidosis B1 variant is R178H, which has a widespread geographic and ethnic distribution. The highest incidence has been described in Portugal, which has been suggested as the point of origin of this mutation. Biochemical characterization of this lysosomal disease is carried out using negatively charged synthetic alpha subunit-specific sulfated substrates, since Hex A isoenzyme heat-inactivation assays are not applicable. However, the determination of the apparent activation energy of Hex using the neutral substrate 3,3'-dichlorophenolsulfonphthaleinyl N-acetyl-ß-D-glucosaminide, may offer a valid alternative. The presence of an alpha subunit in the alphaß heterodimer Hex A means that its activation energy (41.8 kJ/mol) is significantly lower than that of the ßß homodimer Hex B (75.1 kJ/mol); however, as mutation inactivates the alpha subunit, the Hex A of the B1 variant presents an activation energy that is similar to that of the Hex B isoenzyme.
- 1 January 2003
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 17 (6) , 271-275
Chitotriosidase activity in plasma and mononuclear and polymorphonuclear leukocyte populations
In the general population, about 5% of individuals are homozygotic and 35% are heterozygotic carriers for chitotriosidase (ChT) deficiency. Activated macrophages are considered to be the main source of plasma ChT activity, which permits the biochemical characterization of homozygote deficients. However, in the case of detecting heterozygotic carriers, the results are often inconclusive. The activities of ChT in plasma and mononuclear (MN) and polymorphonuclear (PMN) leukocytes were determined in 169 control subjects (72 males and 97 females) with a mean age (± SD) of 47.5±9.7 years (range 18–96 years). The specific enzyme activity was in PMN leukocytes >MN leukocytes >plasma, with a highly significant partial correlation being found between the activities of ChT in plasma and PMN leukocytes (r=0.578, PP<0.001). No significant correlation was found for enzyme activities in MN (r=0.105) or in PMN leukocytes (r=0.043). The results obtained suggest that, in normal physiological conditions, PMN leukocytes may secrete ChT to the plasma. Although the activities of ChT in MN and PMN leukocytes are not affected by demographic factors, it is not possible to use them for the biochemical detection of ChT‐deficient heterozygotic carriers. J. Clin. Lab. Anal. 17:271–275, 2003.
- 1 January 2003
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 17 (6) , 271-275
Chitotriosidase activity in plasma and mononuclear and polymorphonuclear leukocyte populations
In the general population, about 5% of individuals are homozygotic and 35% are heterozygotic carriers for chitotriosidase (ChT) deficiency. Activated macrophages are considered to be the main source of plasma ChT activity, which permits the biochemical characterization of homozygote deficients. However, in the case of detecting heterozygotic carriers, the results are often inconclusive. The activities of ChT in plasma and mononuclear (MN) and polymorphonuclear (PMN) leukocytes were determined in 169 control subjects (72 males and 97 females) with a mean age (± SD) of 47.5±9.7 years (range 18–96 years). The specific enzyme activity was in PMN leukocytes >MN leukocytes >plasma, with a highly significant partial correlation being found between the activities of ChT in plasma and PMN leukocytes (r=0.578, PP<0.001). No significant correlation was found for enzyme activities in MN (r=0.105) or in PMN leukocytes (r=0.043). The results obtained suggest that, in normal physiological conditions, PMN leukocytes may secrete ChT to the plasma. Although the activities of ChT in MN and PMN leukocytes are not affected by demographic factors, it is not possible to use them for the biochemical detection of ChT‐deficient heterozygotic carriers. J. Clin. Lab. Anal. 17:271–275, 2003.
- 1 May 2002
- Published by Elsevier in Clinical Biochemistry
- Vol. 35 (3) , 251-254
Comparison between the Cobas Integra immunoassay and high-performance liquid chromatography for therapeutic monitoring of carbamazepine
- 1 May 2002
- Published by Elsevier in Clinical Biochemistry
- Vol. 35 (3) , 251-254
Comparison between the Cobas Integra immunoassay and high-performance liquid chromatography for therapeutic monitoring of carbamazepine
- 25 September 2001
- Published by Elsevier in Clinica Chimica Acta
- Vol. 312 (1-2) , 123-127
Assessment of copper status in pregnancy by means of determining the specific oxidase activity of ceruloplasmin
- 25 September 2001
- Published by Elsevier in Clinica Chimica Acta
- Vol. 312 (1-2) , 123-127
Assessment of copper status in pregnancy by means of determining the specific oxidase activity of ceruloplasmin